Compare Dyne Therapeutics Inc. Common Stock (DYN) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs State Street Real Estate Select Sector SPDR ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while State Street Real Estate Select Sector SPDR ETF trades at $41.83 (market cap $7.83B). The key difference: State Street Real Estate Select Sector SPDR ETF is far larger — about 2.7× Dyne Therapeutics Inc. Common Stock's market cap, and State Street Real Estate Select Sector SPDR ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and State Street Real Estate Select Sector SPDR ETF for 77 Days on average.
| DYN | XLRE | |
|---|---|---|
Market Cap | $2.86B | $7.83B |
Volume | 3,341,579 | 5,853,296 |
Sector | Health | Sector/Thematic |
52-Week High | $26.78 | $46.01 |
52-Week Low | $14.60 | $40.01 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
XLRE, the State Street Real Estate Select Sector SPDR ETF, trades at $41.83, down 0.21% on the day. The technical outlook is mixed, with a bullish overall signal but bearish moving averages. Key financial ratios are not available in the provided data. Recent news highlights the fund's low expense ratio of 0.08% and its focus on 30 U.S. large-cap real estate holdings, positioning it as a cost-effective domestic real estate exposure tool.
The outlook for XLRE is influenced by competing factors: its low-cost structure is a strength, but the sector faces headwinds from rising bond yields and potential interest rate volatility. Investment opportunity lies in its role as a pure-play U.S. real estate ETF, while risks include macroeconomic sensitivity and competition from more diversified or thematic real estate funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →
